CLSN

Shares of Celsion (NASDAQ:CLSN) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share increased 32.00% over the past year to ($0.17), which missed the estimate of ($0.13).Revenue of $125,000 unchanged by 0.00% year over year, which beat the estimate of $80,000.Outlook Earnings guidance hasn't been issued by the company for now.Celsion hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 16, 2020View more earnings on CLSNTime: 11:00 AMET Webcast URL: https://edge.media-server.com/mmc/p/n6e4r5nwPrice Action Company's 52-week high was at $6.5052-week low: $0.43Price action over last quarter: down 51.53%Company Overview Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 16, 2020 * Stocks That Hit 52-Week Lows On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Celsion (NASDAQ:CLSN) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 32 percent increase over losses of $(0.25) per share from the same

Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.

CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies   LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion

ompletes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion's Capitalization New Agreement Ensures A Strong Balance Sheet and Additional Operating